X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Handok is exclusively responsible for the promotion, marketing, sales and distribution of Pivlaz (clazosentan sodium), the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage, in South Korea.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Product Name: Pivlaz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: HANDOK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 14, 2024
Details:
APP13007 (clobetasol propionate) is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Formosa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 06, 2024
Details:
South Korea approved PIVLAZ™ (clazosentan sodium), an ETAR antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Product Name: Pivlaz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Verily’s proprietary Immune Profiler is a next generation immune mapping platform that will be used to identify GPCR targets that represent new opportunities to modulate immune cell function and ameliorate disease pathology.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
HTL’149 was developed by StaR® technology and SBDD platform, as a once-daily, orally available small molecule and selectively targeting the orphan GPR52 receptor, which is investigated for Schizophrenia.
Lead Product(s): HTL’149
Therapeutic Area: Psychiatry/Psychology Product Name: HTL0048149
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM). TMP-301 is an investigational candidate for the treatment of alcohol and substance use disorders.
Lead Product(s): TMP-301
Therapeutic Area: Psychiatry/Psychology Product Name: TMP-301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Lead Product(s): HTL0039732
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2022
Details:
The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic screening.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Kallyope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2022
Details:
HTL0016878 was designed by Heptares using its proprietary structure-based drug design platform and is the first compound, selected from a series of selective M4 agonists, to progress into clinical studies.
Lead Product(s): HTL0016878
Therapeutic Area: Psychiatry/Psychology Product Name: HTL0016878
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $2,700.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement December 24, 2021
Details:
The collaboration will utilize Sosei Heptares’ fully structurally enabled GPCR target proteins, isolated and stabilized using its proprietary StaR® (stabilized receptor) platform technology.
Lead Product(s): Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Twist Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
